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Abstract
Background:  Various cancer cells, including those of colorectal cancer (CRC), release
microvesicles (exosomes) into surrounding tissues and peripheral circulation. These microvesicles
can mediate communication between cells and affect various tumor-related processes in their
target cells.
Results: We present potential roles of CRC cell-derived microvesicles in tumor progression via a
global comparative microvesicular and cellular transcriptomic analysis of human SW480 CRC cells.
We first identified 11,327 microvesicular mRNAs involved in tumorigenesis-related processes that
reflect the physiology of donor CRC cells. We then found 241 mRNAs enriched in the
microvesicles above donor cell levels, of which 27 were involved in cell cycle-related processes.
Network analysis revealed that most of the cell cycle-related microvesicle-enriched mRNAs were
associated with M-phase activities. The integration of two mRNA datasets showed that these M-
phase-related mRNAs were differentially regulated across CRC patients, suggesting their potential
roles in tumor progression. Finally, we experimentally verified the network-driven hypothesis by
showing a significant increase in proliferation of endothelial cells treated with the microvesicles.
Conclusion: Our study demonstrates that CRC cell-derived microvesicles are enriched in cell
cycle-related mRNAs that promote proliferation of endothelial cells, suggesting that microvesicles
of cancer cells can be involved in tumor growth and metastasis by facilitating angiogenesis-related
processes. This information will help elucidate the pathophysiological functions of tumor-derived
microvesicles, and aid in the development of cancer diagnostics, including colorectal cancer.
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Background
During growth or activation, a variety of cell types, includ-
ing hematopoietic, epithelial, and tumor cells, shed small
membrane vesicles called microvesicles (exosomes) [1-6].
These microvesicles, which are 30-200 nm in diameter,
are derived from the endosomal membrane compartment
following the fusion of multivesicular bodies with the
plasma membrane. Cells also release microvesicles
directly by the outward budding of the plasma membrane
in a calcium-dependent manner [4]. Microvesicles have
been also found in various body fluids, such as plasma,
malignant pleural effusion, and urine [7-10]. The numer-
ous proteins and bioactive lipids contained in microvesi-
cles differ in composition depending on the types and
states of donor cells. Recent studies have reported that
microvesicles also contain mRNA [11-15]. Although their
biological roles are not completely understood, microves-
icles have been shown to stimulate target cells by transfer-
ring microvesicular components (e.g., plasma membrane
receptors and bioactive lipids) into target cells, transfer-
ring infectious particles, such as human immunodefi-
ciency virus and prions, and delivering microvesicular
mRNAs to target cells (called horizontal transfer of genetic
materials), where they are translated into functionally
active proteins [12-15]. These findings suggest that micro-
vesicles are not cellular debris but are communicasomes,
which are extracellular organelles with distinct roles in
intercellular communication [5,16].
Colorectal cancer (CRC) is one of the most frequent
malignant tumors in Western countries [17]. CRC cells
also release microvesicles [5,18], and the revelation from
proteomic studies that CRC cell-derived microvesicles
contain several hundred proteins has helped elucidate the
functions of microvesicles at the protein level [5,18]. It
has also been reported that RNA-lipid complexes are
released from the plasma membrane of CRC cells, and
CRC patients show significantly elevated serum mRNA
levels over those of healthy subjects [19,20]. In view of the
higher concentration of RNase in the serum of patients
with cancer, these circulating mRNAs are likely to be
present in a particle-associated form [21,22]. Collectively,
these observations suggest that CRC cell-derived micro-
vesicles carry mRNA, together with proteins and lipids,
which may exert a functional influence on CRC-related
processes.
To improve the understanding of the potential roles of
CRC cell-derived microvesicles in CRC-related processes,
we conducted a systems approach to the CRC cell-derived
microvesicles using transcriptome analysis of the micro-
vesicles derived from SW480 cells, a human CRC cell line,
and the donor CRC cells. Our systems approach to CRC
cell-derived microvesicles provided 11,327 microvesicular
transcripts that are involved in various tumor-related
processes, which suggests that the microvesicles reflect the
physiology of the donor CRC cells. Furthermore, we
found that CRC-derived microvesicles enriched with cell
cycle-related mRNAs that showed differential expression
patterns in CRC patient data. Moreover, microvesicles
stimulated proliferation of endothelial cells, suggesting
that CRC-derived microvesicles can be involved in tumor
growth and metastasis by facilitating angiogenesis-related
processes. Our results provide a number of indicators that
will not only increase the understanding of pathophysio-
logical functions of tumor derived microvesicles, but also
may stimulate the development of novel methods for can-
cer diagnostics including CRC.
Results
Purification and characterization of microvesicles derived 
from human SW480 cells
We obtained highly purified microvesicles secreted by
human colorectal adenocarcinoma SW480 cells using a
previously described method with several modifications
(Figure 1A) [5]. Microvesicles were isolated from the cul-
ture supernatant using a combination of differential cen-
trifugation to remove cells and cellular debris,
ultrafiltration through a 100-kilodaltons hollow-fiber
membrane to concentrate the microvesicles, and ultracen-
trifugation onto sucrose cushions. The purified microves-
icles were treated with RNase A to degrade any non-
microvesicular RNA and then further purified using iodix-
anol density-gradient ultracentrifugation to remove non-
membranous proteins, protein aggregates, and denatured
microvesicles. The microvesicles settled at a density of
~1.098 g/mL, as indicated by the microvesicular marker
proteins CD63 and CD81 (Figure 1B). An examination of
the purified microvesicles using electron microscopy
revealed that nearly all were small closed vesicles, approx-
imately 40-150 nm in size (Figure 1C) [5,18]. Further-
more, β-actin, HSP90, ezrin, and Rab5A, which are known
microvesicular proteins, were detected in the purified
microvesicles, whereas GM130, a protein present in the
cis-Golgi apparatus, and cytochrome c, a mitochondrial
protein present in apoptotic bodies, were not detected
(Figure 1D) [5].
Transcriptomic analysis of microvesicles
For transcriptomic profiling, we extracted high-quality
total RNA from both purified microvesicles and SW480
cells (Figure 1A), as indicated by the high RNA integrity
numbers of Bioanalyzer profiles: 9.0 for cellular RNA and
8.7 for microvesicular RNA (Figure 2A). The microvesicu-
lar  β-actin and β-catenin transcripts were further con-
firmed by RT-PCR analysis (Figure 2B). We then prepared
cRNA and hybridized the cRNA to Illumina Human-6 v2
Expression BeadChips (four technical replicates each for
the microvesicular and cellular mRNAs; Figure 1A). The
technical replicates had a high reproducibility, as shownBMC Genomics 2009, 10:556 http://www.biomedcentral.com/1471-2164/10/556
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by the high Pearson's correlation (> 0.99) between the
normalized intensities of two independent arrays of
microvesicular and cellular RNAs (Figure 2C and addi-
tional file 1). Moreover, mRNA abundances from SW480
cells and microvesicles (Figure 2D) were also highly corre-
lated (correlation coefficient = 0.9778), indicating that
similar amounts of most cellular mRNAs also exist in
microvesicles.
From the mRNA measurements, we found that most of
the mRNA transcripts from SW480 cells (11,624) also
existed in SW480-derived microvesicles (11,327) (addi-
tional file 2). This finding is similar to that of Skog et al.
Purification and characterization of microvesicles derived from SW480 cells Figure 1
Purification and characterization of microvesicles derived from SW480 cells. A) Overview of the procedure used 
to identify microvesicular and cellular mRNA from SW480 cells. B) Western blot of microvesicular marker proteins CD63 and 
CD81 in fractions from iodixanol density gradients. C) Electron microscopy of the purified microvesicles. Bars represent 100 
nm. D) Western blot of β-actin, HSP90, Ezrin, and Rab5A (microvesicular proteins), and GM130 (a protein found in the cis-
Golgi apparatus), and cytochrome c (a mitochondrial protein found in apoptotic bodies). Neither GM130 nor cytochrome c 
were detected in microvesicles, despite using 10 times more microvesicles (10 μg) than the amount used to detect other 
microvesicular proteins (1 μg). The symbols of WCL and MVs represent whole cell lysate and microvesicles, respectively.BMC Genomics 2009, 10:556 http://www.biomedcentral.com/1471-2164/10/556
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(2008), who detected about 27,000 transcripts in gliob-
lastoma-derived microvesicles [15]. In contrast, two previ-
ous studies [13,14] reported that only subsets of genes in
endothelial progenitor cells and mouse mast cells (MC/9)
were selectively sorted into microvesicles. A comparison
of microvesicular mRNAs in our study with those in two
previous studies [14,15] (Figure 3A) showed that the
majority of microvesicular mRNAs in those studies were
also detected in our study: 10,222 overlapping transcripts
from glioblastoma cells and 512 from mouse mast cell
MC/9 (additional file 3). Using RT-PCR, we confirmed
that among the microvesicular transcripts shared by
SW480 and glioblastoma microvesicles [15] but not
detected in mast cell microvesicles, RAB13, CXCR4, MYC,
and FAS transcripts were present in the SW480-derived
microvesicles (Figure 3B).
Cellular processes overrepresented by the microvesicular 
mRNAs
We then identified functions overrepresented by the
11,327 microvesicular mRNAs using BiNGO, a Cytoscape
plugin [23]. Figure 4A shows a GO tree representing a
hierarchical structure of GOBPs, in which the colored
nodes in the GO tree indicate significantly overrepre-
sented GOBPs (P < 0.05). The overrepresented cellular
processes were categorized into the following groups: cell
cycle, cell death, intracellular signaling, intracellular trans-
port, and metabolic processes of protein, RNA, and DNA
(boxes in Figure 4A). Among these groups, Figure 4B
shows the four groups of GOBPs closely associated with
tumor progression: cell cycle- and mitosis-related proc-
esses, apoptosis-related processes, tumor-related intracel-
lular signaling pathways, and vesicle-mediated transport
pathways that might be involved in the formation and
Isolation and transcriptomic analysis of microvesicular RNA Figure 2
Isolation and transcriptomic analysis of microvesicular RNA. A) Bioanalyzer results of total RNA isolated from micro-
vesicles and SW480 cells. The third and fourth peaks correspond to 18S and 28S rRNA, respectively. Images of gel electro-
phoresis are also shown. B) Gel electrophoresis of microvesicular and cellular β-actin and β-catenin mRNA amplified by RT-
PCR. C) Scatterplots of microvesicular and cellular mRNA expression levels showing log2 intensities in the first and the second 
arrays (Pearson's correlation coefficients: ρ = 0.9917 and 0.9920 for microvesicular RNA and cellular RNA, respectively). D) 
Scatterplot of median log2 intensities of the four microvesicle replicates versus those of their donor cells (ρ = 0.9778).BMC Genomics 2009, 10:556 http://www.biomedcentral.com/1471-2164/10/556
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secretion of microvesicles. Collectively, these observa-
tions suggest that microvesicular mRNAs probably can
contribute to promoting tumor progression in target cells
when these mRNAs are transferred into neighboring target
cells.
Enrichment of cell cycle-related mRNAs in microvesicles
Despite the similarities at the global level between the
microvesicular and cellular mRNAs, we identified 241
mRNAs whose expression levels were two fold higher in
the microvesicles than in SW480 cells (microvesicle-
enriched mRNAs; Figure 5A and additional file 4). We
also identified 1,461 mRNAs whose expression levels
were two fold higher in SW480 cells than in microvesicles
(cell-enriched mRNAs). To characterize the processes
overrepresented by the microvesicle-enriched genes, we
performed GO enrichment analysis using BiNGO, where
among the 241 microvesicle-enriched genes, 136 genes
with GO annotations were used (additional file 5). Unex-
pectedly, cell cycle-related processes (GO term "cell
cycle"), including M-phase and mitosis (dark red nodes in
Figure 5B), are highly overrepresented by 27 out of 136
microvesicle-enriched genes (P = 2.98 × 10-8). Moreover,
20 of these 27 genes also belong to M-phase cell cycle
processes (red box in Figure 5B, P = 6.27 × 10-13).
To predict the potential roles of the 27 cell cycle-related
microvesicle-enriched genes at the molecular level, we
then reconstructed a biological network (Figure 5C)
describing the overrepresented cell cycle-related processes
(Figure 5D). The network was reconstructed using the 27
genes belonging to the cell cycle GO term and their first
and second interaction neighbors obtained from HPRD,
BIND, and BioGRID interaction databases. In the net-
work, yellow nodes represent the 27 microvesicle-
enriched genes, 20 of which closely interact with cell
cycle-related processes. The network shows that the
microvesicle-enriched genes closely interact with key
pathways in the cell cycle, including cyclin-dependent
kinases 8 and N3 (CDK8 and CDKN3), centrosomal pro-
tein 55 kilodaltons (CEP55), kinensin family members
(KIF15  and  KIF23), centromere proteins (CENPE  and
CENPF), anillin (ANLN), PDZ-binding kinase (PBK), and
NIMA-related kinase 2 (NEK2). Collectively, these obser-
vations suggest that the microvesicle-enriched genes may
contribute to the increased cell proliferation of target cells
during tumor progression by modulating activities of cell
cycle-related pathways.
To examine the clinical implications of the 241 microves-
icle-enriched genes, we collected from the GEO database
[24] two transcriptomic datasets (GSE2109 and
GSE5206), including global mRNA measurements from
CRC patients at various stages, and then used cluster anal-
ysis to investigate whether these genes are differentially
expressed among patients (additional file 6). Interest-
ingly, a cluster comprising 36 of the 241 microvesicle-
enriched genes showed consistent differential expression
patterns across the patients in the two independent data-
sets (Figure 5D): the expression levels of the genes in each
patient sample were compared to their average expression
levels in the individual datasets. Of these, 15 of the 36
genes showing differential expression patterns are
involved in M-phase-related processes (red box in Figure
5B; e.g., spindle formation, kinetochore assembly, chro-
mosome segregation, and cytokinesis) that are either
involved in or interact with components involved in the
M-phase of the mitotic cell cycle (see diamond nodes in
Figure 5C and additional file 7). Note that 17 of the 36
genes belong to cell cycle GOBP. These observations sug-
gest that microvesicle-enriched genes reflect their poten-
tial roles in tumor progression in patients with CRC.
Comparison with other microarray studies and validation of  the microvesicular and cellular mRNAs detected in our study Figure 3
Comparison with other microarray studies and vali-
dation of the microvesicular and cellular mRNAs 
detected in our study. A) Comparison among the number 
of mRNAs detected in microvesicles derived from mouse 
mast cells (MC/9) [14], glioblastoma (GBM) [15] and human 
SW480 CRC cells. B) Gel electrophoresis of amplified micro-
vesicular and cellular mRNA. Presence of several microvesic-
ular mRNAs including RAB13, CXCR4, MYC, and FAS were 
confirmed using RT-PCR. The symbol of MVs represents 
microvesicles.BMC Genomics 2009, 10:556 http://www.biomedcentral.com/1471-2164/10/556
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Stimulation of endothelial cell proliferation by 
microvesicles
Based on the observations that microvesicle-enriched
mRNAs are highly associated with M-phase-related proc-
esses (Figure 5), we generated a network-driven hypothe-
sis that CRC cell-derived microvesicles promote the
proliferation of neighboring cells in the tumor microenvi-
ronment by increasing their cell cycle activities via the
horizontal transfer of microvesicular mRNAs, as several
recent studies have clearly demonstrated [12-15]. To
experimentally verify this hypothesis, we investigated
whether CRC cell-derived microvesicles can affect the cell
cycle of endothelial cells. Using RT-PCR, we first con-
firmed that M-phase-related transcripts including CENPE,
KIF15,  CEP55,  CCNA2,  NEK2,  PBK, and CDK8  were
present in the SW480-derived microvesicles (Figure 6A).
When we incubated microvesicles labeled with fluores-
cent dye with HUVECs, we observed a strong red fluores-
cence in the cytoplasm (Figure 6B), indicating that
significant amounts of microvesicles were taken up by the
HUVECs. We then immunostained both phospho-his-
tone H3 (mitosis marker) and α-tubulin to analyze
mitotic spindle formation occurring during the M-phase.
A subpopulation of microvesicle-treated HUVECs, indi-
cated by a strong phospho-histone H3 signal, underwent
mitosis (Figure 6C). Furthermore, at higher magnifica-
tion, we observed these microvesicle-treated HUVECs to
be at metaphase (Figure 6D), a stage of M-phase, and
undergoing cytokinesis with mitotic spindle formation
(Figure 6E). In contrast, HUVECs not treated with micro-
vesicles showed weak histone H3 phosphorylation (Fig-
ure 6C), and none were at metaphase/cytokinesis stages
Cellular processes overrepresented by the mRNAs detected in microvesicles Figure 4
Cellular processes overrepresented by the mRNAs detected in microvesicles. A) A GO tree obtained from BiNGO 
showing the hierarchy of GOBPs overrepresented by mRNAs present in microvesicles (P < 0.05; see the color bar). Node 
colors represent the statistical significance of functional enrichment of the corresponding GOBPs. The white nodes (P > 0.05) 
were added to show the relationships among their downstream nodes. The overrepresented GOBPs were categorized into 
several groups of cellular processes, each of which is indicated by a box. B) The four GOBP groups (cell cycle, apoptosis, intra-
cellular signaling, and intracellular transport) related to tumor progression are shown in detail.BMC Genomics 2009, 10:556 http://www.biomedcentral.com/1471-2164/10/556
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Figure 5 (see legend on next page)BMC Genomics 2009, 10:556 http://www.biomedcentral.com/1471-2164/10/556
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(data not shown). Furthermore, we observed that
HUVECs treated with microvesicles derived from THP-1,
human acute monocytic leukemia cell line showed weak
histone H3 phosphorylation (additional file 8). These
observations clearly support a role for CRC cell-derived
microvesicles in modulating M-phase activities of the cell
cycle and thus promoting proliferation of HUVECs, which
can initiate angiogenesis.
Discussion
This study presents a transcriptomic analysis of CRC cell-
derived microvesicles, among which we identified 11,327
microvesicular transcripts involved in various tumor-
related processes that reflect the physiology of the donor
CRC cells. Among these transcripts, we found 241 mRNAs
enriched in microvesicles beyond their levels in donor
cells, of which 27 were involved in the cell cycle. Moreo-
ver, 20 of these 27 mRNAs were associated with cell cycle
M-phase activities, and 15 of these showed differential
expression patterns in CRC patient data. We then demon-
strated that these mRNAs may modulate activities of M-
phase processes during the cell cycle by reconstructing a
cell cycle network, which showed that the corresponding
proteins belong to and also interact with those involved in
M-phase-related processes. To experimentally verify this
network-driven hypothesis, we demonstrated that CRC
cell-derived microvesicles are delivered to endothelial
cells and stimulate the proliferation of endothelial cells.
Since this proliferation is an essential step in neovascular-
ization, our finding suggests that microvesicles have ang-
iogenic activities.
The preparation of microvesicles that are not contami-
nated with cellular debris, bovine serum-derived micro-
vesicles, or any non-microvesicular mRNA is critical for
transcriptional profiling of microvesicles. As the half-life
of individual microvesicular mRNA transcripts is
unknown, the rapid analysis of microvesicular mRNA is
also very important. We therefore followed our previously
described purification methods with the following two
major modifications [5]. In particular, RNase A treatment
was applied in order to degrade non-microvesicular RNA
derived from damaged cells or leaky microvesicles (Figure
1A). The microvesicles were finally purified using iodixa-
nol density gradient centrifugation, which is much faster
than the conventional sucrose density gradient centrifuga-
tion [14,25]. As a result, the high quality of the microve-
sicular RNA was obtained as indicated by the Bioanalyzer
results (RIN: 8.7).
Growing evidence indicates that tumor-derived microves-
icles are involved in tumor progression via the modula-
tion of tumorigenesis, angiogenesis, immune response,
invasion, and metastasis [1-5]. Moreover, recent studies
have reported that microvesicular mRNA can induce
potent epigenetic changes in target cells, as microvesicular
mRNA is delivered to target cells, where it is translated
into functionally active proteins [11-14]. Our findings
that SW480-derived microvesicular mRNAs are involved
in various tumor-related processes (Figure 4 and Figure 5)
and SW480-derived microvesicles can initiate angiogen-
esis via the stimulation of endothelial cell proliferation
(Figure 6) also suggest that the microvesicular mRNAs
play potential roles in progression of CRC. Furthermore,
SW480-derived microvesicles are enriched with CENPE,
KIF15, CEP55, CCNA2, NEK2, PBK, and CDK8 (Figure 6a)
that are M-phase-related transcripts involved in tumori-
genesis and tumor progression [26-28]. Although we
could not exclude the other possibility, our observations
suggest that SW480-derived microvesicles promote the
proliferation of endothelial cells by increasing their cell
cycle activities via the horizontal transfer of these M-
A biological network describing the cellular processes overrepresented by microvesicle-enriched mRNAs Figure 5 (see previous page)
A biological network describing the cellular processes overrepresented by microvesicle-enriched mRNAs. A) A 
heat map illustrating the expression patterns of the 1,702 genes that exhibited a more than 2-fold difference in the mRNA level 
between microvesicles and cells. For clarity, the expression of each is scaled to a mean of zero with unit variance across all 
eight replicates. The colors represent the relative increase (red) or decrease (green) in the expression level of the correspond-
ing gene in microvesicles compared with the level in cells: 241 and 1,461 genes were overexpressed in microvesicles and in 
cells, respectively. B) A GO subtree showing cell cycle-related GOBPs overrepresented by the 241 microvesicle-enriched 
genes. The color scheme of Figure 4 is repeated. Notably, cell cycle-related GOBPs were strongly overrepresented by 27 
mRNAs, as indicated by the dark-red node colors (see text for details). C) A hypothetical network reconstructed using the 27 
microvesicle-enriched mRNAs belonging to the cell cycle-related GOBPs in (B) and their first and second interaction neighbors 
obtained from protein-protein interaction databases (see Materials and methods). The yellow nodes represent the 27 cell 
cycle-related microvesicle-enriched genes: 20 of the 27 genes closely interact with cell cycle-related processes. The lines 
between the nodes represent protein-protein interactions. The network shows that the microvesicle-enriched genes closely 
interact with key pathways in the cell cycle. D) Cluster heat map comprising 36 of the 241 microvesicle-enriched mRNAs 
showing consistent differential expression patterns across patients in two independent CRC datasets (GSE2109 and GSE5206). 
The diamond nodes in the network (C) represent the 17 nodes shared by the 27 cell cycle-associated mRNAs and 36 mRNAs; 
of the 17 nodes, 15 (labeled in red) are associated with M-phase-related processes.BMC Genomics 2009, 10:556 http://www.biomedcentral.com/1471-2164/10/556
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Stimulation of endothelial cell proliferation by microvesicles Figure 6
Stimulation of endothelial cell proliferation by microvesicles. A) Gel electrophoresis of amplified microvesicular M-
phase-related transcripts. Presence of CENPE, KIF15, CEP55, CCNA2, NEK2, PBK and CDK8 were confirmed using RT-PCR. B) 
Immunofluorescence of HUVECs treated with microvesicles labeled with PKH26 (red). Cells were stained with anti-calnexin 
antibody, an endoplasmic reticulum marker protein (green). C-E) Immunostaining of HUVECs with anti-phospho-histone H3 
(green) and anti-α-tubulin antibodies (red). After 12 hours, microvesicle-treated endothelial cells were at metaphase (D) and 
cytokinesis with mitotic spindle formation (E). None of the untreated control endothelial cells were in metaphase or cytokine-
sis stages. Scale bars represent 10 μm (B, D, E) and 40 μm (C). The symbol of PH3 represents phospho-histone H3.BMC Genomics 2009, 10:556 http://www.biomedcentral.com/1471-2164/10/556
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phase-related microvesicular mRNAs. Further studies on
microvesicles derived from other colon cancer cells would
provide valuable data. Thus, the inhibition of either
microvesicle shedding or modulation of microvesicular
function has been proposed as worthwhile approaches to
cancer therapy. Recently, Al-Nedawi et al. (2009) showed
that the treatment of Diannexin, which inhibits the
uptake of the A431 (human squamous cell carcinoma cell
line)-derived microvesicles into endothelial cells, to A431
tumor xenografts in mice led to a reduction of tumor
growth rate and microvascular density [29]. Thus, our
findings above suggest that the inhibition of biogenesis,
trafficking or function of the CRC-derived microvesicles
also can offer a novel therapeutic approach for CRC.
Despite the progress in understanding and treating CRC,
it remains a leading cause of mortality worldwide [30]. A
significant improvement in survival would be expected
with early diagnosis of CRC. Several studies have reported
that the level of tumor-derived microvesicles is elevated
significantly in the serum or the ascites fluid of cancer
patients [8,31,32]. Recently, Taylor et al. proposed that
microRNA profiling of circulating tumor microvesicles
could potentially be used to identify diagnostic markers
for human ovarian cancer [33]. Thus, our finding that the
microvesicular mRNA reflects the mRNA signature of the
parental CRC suggests that the microvesicular mRNA may
be a useful diagnostic and/or prognostic marker of early
stage cancer and could be evaluated in a non-invasive
manner. Possible CRC marker candidates can be predicted
as the microvesicle-enriched mRNAs that show colon-spe-
cific expression patterns (additional file 9).
Conclusion
These study present potential roles of CRC cell-derived
microvesicles in tumor progression via a global compara-
tive microvesicular and cellular transcriptomic analysis of
human SW480 CRC cells. However, it is not clear how
these microvesicular mRNAs cooperatively act with other
microvesicular components such as lipids and proteins in
the target cells. Future studies on collective pathophysio-
logical roles of such microvesicular components in mod-
ulating dynamically tumor-related networks in the target
cells will be valuable in clarifying the microvesicle-
involved communication, including that in human CRC,
and further unraveling the complexity of the intercellular




SW480 (human colorectal adenocarcinoma cells) and
THP-1 (human acute monocytic leukemia cells) were cul-
tured in RPMI-1640 medium (Invitrogen Corporation,
Carlsbad, CA) supplemented with 10% heat-inactivated
fetal bovine serum (Invitrogen Corporation), 100 U/mL
penicillin, and 0.1 mg/ml streptomycin. human umbilical
vein endothelial cells (HUVECs) were isolated from
freshly delivered umbilical cords and maintained as
described previously [2].
Purification of microvesicles
The SW480 cells were washed twice with PBS and then
incubated in serum-free RPMI-1640. After 24 h incuba-
tion, the conditioned medium was collected, centrifuged
at 500 × g for 10 minutes, and then centrifuged twice at
2,000 × g for 15 minutes. The supernatant was concen-
trated using a QuixStand Benchtop System (GE Health-
care, Bucks, UK) with a 100-kilodaltons hollow fiber
membrane (GE Healthcare), placed upon 0.5 mL of 0.8
and 2.0 M sucrose cushions in buffer (20 mM HEPES, 150
mM NaCl, pH 7.4), and then centrifuged at 100,000 × g
for 2 hours. The microvesicles were harvested from the
interface between the 0.8 and 2.0 M sucrose cushions.
After treatment with 20 μg/ml RNase A (Roche Diagnos-
tics, Mannheim, Germany) for 30 minutes at room tem-
perature, the sample was diluted 10-fold in PBS, placed
upon 0.35 ml of 0.8 M and 0.15 ml of 2.0 M sucrose cush-
ions, and centrifuged at 100,000 × g  for 2 hours. The
microvesicles were harvested and mixed with an equal
volume of 60% iodixanol solution (Axis-Shield PoC AS,
Oslo, Norway), to give 30% iodixanol. This sample was
placed at the bottom of a tube and overlaid with 20% and
5% iodixanol. After centrifugation at 200,000 × g for 2
hours, 10 fractions of equal volume were removed from
the top of the gradient. The microvesicle-enriched fraction
was diluted with 9 ml of PBS and then centrifuged at
100,000 × g for 2 hours. Finally, the purified microvesicles
were resuspended in PBS and used immediately for the
preparation of microvesicular RNA.
Transmission electron microscopy
The purified microvesicles were applied to glow-dis-
charged carbon-coated copper grids (EMS, Matfield, PA).
After allowing the microvesicles to absorb for 3 minutes,
the grids were rinsed with droplets of de-ionized water
and positive-stained with a mixture of 2% methylcellulose
and 4% uranylacetate (Ted Pella, Redding, CA). Electron
micrographs were recorded using a JEM 1011 microscope
(Jeol, Japan) at an acceleration voltage of 100 kilovolt.
Western blot
Whole cell lysate and microvesicles were separated by
SDS-PAGE and then transferred to a polyvinylidene deflu-
oride membrane. The membrane was blocked, incubated
with antibodies followed by secondary antibodies conju-
gated to horseradish peroxidase and subjected to
enhanced chemiluminescence.BMC Genomics 2009, 10:556 http://www.biomedcentral.com/1471-2164/10/556
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Preparation of total RNA and reverse-transcription 
polymerase chain reaction
Total RNA was extracted from SW480 cells and purified
microvesicles by a single-step isolation method using TRI-
zol reagent (Invitrogen Corporation). The RNA was re-
suspended in diethyl pyrocarbonate-treated water and
quantified by UV absorbance at 260/280 nm. Reverse-
transcription polymerase chain reaction (RT-PCR) was
performed with 100 ng of total RNA and 100 nM forward
and reverse primers, using a One Step SYBR RT-PCR kit
(Takara, Otsu, Japan). The primer sequences are provided
in additional file 10. A LightCycler system (Roche Diag-
nostics, Mannheim, Germany) was used with the follow-
ing thermal profile: initial denaturation at 95°C for 10
minutes, followed by 45 cycles of 95°C for 15 seconds,
60°C for 15 seconds, and 72°C for 10 seconds.
Microarray analysis
For transcriptional profiling, we used Illumina Human-6
v2 Expression BeadChips (Illumina, San Diego, CA),
which include a bead pool of ~48,000 unique bead types
corresponding to 47,294 transcripts [13]. The quality of
the cellular and microvesicular total RNA was analyzed
using an Agilent 2100 Bioanalyzer. 640 ng of total RNA
from the microvesicles and SW480 cells were reverse-tran-
scribed and amplified, according to the protocols in the
Illumina TotalPrep RNA amplification kit manual
(Ambion, Austin, TX). Then, in vitro transcription was car-
ried out to generate complementary RNAs. 1.5 μg of com-
plementary RNAs was hybridized onto each array (four
replicates for the microvesicles and SW480 cells) and then
labeled with Cy3-streptavidin (Amersham Biosciences,
Little Chalfont, UK). The array was then scanned using a
Bead Station (Illumina). The full dataset was submitted to
Gene Expression Omnibus (GEO) under submission
number GSE9589. The probe intensities for the microves-
icles and SW480 cells were separately normalized using
quantile normalization in beadarray 1.6, an R/Bioconduc-
tor package [34]. The probes were annotated using lumi
1.4, an R/Bioconductor package. To determine present
probes, we applied the following Gaussian mixture mod-
eling method [35]; 1) two Gaussian probability density
functions, one for the absent probes and the other for the
present ones, were fitted to the distribution of the
observed probe intensity; and 2) the probes whose maxi-
mum intensities in all four replicates were higher than the
threshold intensity (α: the intensity where two fitted
Gaussian probability density functions meet) were deter-
mined to be present. Also, the microvesicles-enriched
mRNAs were identified as the ones showing more than 2-
fold changes between the median intensities of four repli-
cates in microvesicles than those in SW480 cells. For a
comparison of the microvesicular mRNAs in this study
with those from the previous two studies of glioblastoma-
and mouse mast cell (MC/9)-derived microvesicles
[13,14], we used Affymetrix/Illumina annotation infor-
mation (GPL1261, GEO accession), human-WG6 annota-
tion, and human and mouse orthology from Mouse
Genome Informatics (MGI 4.0, http://www.informat
ics.jax.org).
Functional enrichment analysis and network analysis
We used BiNGO version 2.0, a Cytoscape plug-in [23], to
identify biological processes overrepresented by the
mRNAs detected in the microvesicles (also by the the
microvesicle-enriched mRNAs). In a Gene Ontology (GO)
tree, each node and node color represent the correspond-
ing enriched Gene Ontology Biological Processes (GOBP)
and the associated statistical significance (P values com-
puted from a hypergeometric hypothesis test in BiNGO),
respectively. To describe the cell cycle related processes in
which the microvesicle-enriched mRNAs are involved and
the interactions among the proteins corresponding to
such mRNAs, we reconstructed an initial biological net-
work using the proteins and their first and second neigh-
bors [36], obtained from BIND http://www.bind.ca,
HPRD http://hprd.org, and BioGrid http://www.thebiog
rid.org databases, to include as many as the 27 cell cycle
related microvesicle-enriched genes. To generate a com-
pact network (Figure 4B) from the complex initial net-
work, we then removed the nodes that were not
connected with the 27 microvesicle-enriched genes, but
kept the nodes whose removal would disconnect the 27
microvesicle-enriched genes from the main network.
PKH26-labeled microvesicles
Purified microvesicles were labeled with PKH26 red fluo-
rescent labeling kit (Sigma-Aldrich, St. Louis, MO) accord-
ing to the manufacturer's instructions. The labeled
microvesicles (1 μg/ml) were allowed to bind for 1 hour
at 4°C, washed with PBS, and then incubated at 37°C for
24 hours. Cells were fixed with 4% paraformaldehyde,
washed, and stained with calnexin (endoplasmic reticu-
lum marker protein). The uptake of labeled microvesicles
by HUVECs was determined using an FV1000 confocal
microscope (Olympus, Tokyo, Japan) equipped with a
UPlanSApo 40×/0.75 objective lens of red fluorescence
intensity.
Immunocytochemistry
HUVECs grown on 0.1% gelatin-coated glass coverslips
were incubated with microvesicles (1 μg/ml) for the indi-
cated times. The cells were fixed with 4% paraformalde-
hyde, permeablilized with 0.2% Triton X-100, and then
incubated with anti-phospho-histone H3 (Ser 10)
(Upstate Biotechnology, Lake Placid, NY) and anti-α-
tubulin antibodies (Sigma-Aldrich). After treatment with
AlexaFluor-conjugated secondary antibodies (Invitrogen
Corporation), the cells were counterstained with HoechstBMC Genomics 2009, 10:556 http://www.biomedcentral.com/1471-2164/10/556
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(Sigma-Aldrich). The FV1000 Olympus confocal micro-
scope was used for the analysis.
Accession numbers
The full dataset is submitted to Gene Expression Omnibus
under submission number series, GSE9589.
Abbreviations
CRC: colorectal cancer; HUVECs: human umbilical vein
endothelial cells; RT-PCR: reverse-transcription polymer-
ase chain reaction; GEO: Gene Expression Omnibus; GO:
gene ontology; GOBPs: gene ontology biological proc-
esses; rRNA: ribosomal RNA.
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Additional material
Additional file 1
Scatterplots of microvesicular and cellular mRNA. Four replicate arrays 
were performed. Two arrays among #1, 2, 3, and 4 are shown in each 
scatterplot. The x- and y-axes represent probe intensity (log2). ρ indicates 
the correlation coefficient between two arrays used in each scatterplot.




mRNAs identified as present in microvesicles and cells. The table shows 
mRNAs identified as present in (A) SW480 cell-derived microvesicles and 
(B) SW480 cells using the Gaussian mixture modeling method.




A comparison of microvesicular mRNAs in our study with those in two 
previous studies. The table shows microvesicular mRNAs detected in 1) 
MC/9-derived microvesicles from Valadi et al[1], 2) glioblastoma 
(GBM)-derived microvesicles from Skog et al[2], and 3) SW480 cell-
derived microvesicles from our study. For MC/9 data, MGI 4.0 human-
mouse orthology was used to map mouse genes into their human ortholo-
gous genes http://www.informatics.jax.org.




Two hundred and forty-one microvesicle-enriched mRNAs. The table 
shows 241 mRNAs whose expression levels were two fold higher in the 
microvesicles than in SW480 cells.




GOBPs overrepresented by the 241 microvesicle-enriched mRNAs. The 
table shows GOBPs overrepresented by the 241 microvesicle-enriched 
mRNAs, 136 genes with GO annotations were used.




A heat map showing expression patterns of the 241 microvesicle-
enriched mRNAs in two independent colorectal cancer data sets 
(GSE2109 and GSE5206). Note that a cluster comprising 36 mRNAs, 
denoted by the box, showed consistent differential expression patterns 
across the patients in the two data sets. Of these, 15 are associated with 
M-phase-related cell cycle processes (see text for details).




Various mRNA subsets described in the text. The table shows various 
mRNA subsets of the 27 cell-cycle-associated microvesicle-enriched 
mRNAs and 36 mRNAs identified from the patients with CRC described 
in the text.




The effect of THP-1-derived microvesicles on endothelial cell prolifer-
ation. After 12 hours, microvesicle-treated endothelial cells were immu-
nostained with anti-phospho-histone H3 (green) and anti-α-antibodies 
(red). Scale bars represent 40 μm.




A subset of the 15 genes (CCNA2, CDKN3, CENPF, KIF23, and 
NEK2) whose expression is relatively enriched in CRC compared to 
other tissues and cells. Note that the 15 genes are those shared between 
20 M-phase-related genes and 36 genes with differential expression pat-
terns in patients with CRC.




Specific primer pairs for RT-PCR. The table shows the primers used in 
this study.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
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